Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br In this study the blood levels of OHdG as

    2019-09-23


    In this study, the blood levels of 8-OHdG as a biomarker of DNA damage by oxidative stress combined with the common tumor markers CEA and CA15-3 were evaluated in benign and malignant BC in comparison with their levels in normal healthy women. The levels of the studied parameters in different invasive stages of BC (I-IV) were investigated to distinguish the early inva-sive stages (I and II) of BC from patients with benign tumor and to test 8-OHdG as a biomarker for risk estimation, early screening, and for further detection of BC.
    Materials and Methods
    Subjects
    This study included 50 female patients with benign breast mass and 50 female patients with malignant BC mainly of post-menopausal age and not receiving antitumor therapy (Table 1). Patients were selected and examined at the oncology clinic of King Abdallah Medical City, in Makkah, during the MF498 between October 2014 and March 2017. The controls are 50 volunteer healthy women. Fasting blood sample was collected. Serum was separated by centrifugation (3500-4000 rpm) of clotted samples and stored at 20 C until analysis. r> Ethics Statement
    This study was carried out in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by
    Table 2 Serum Levels of Studied Biomarkers in Normal, Benign, and Malignant Groups of Patients
    Normal Benign Malignant
    N
    CEA, ng/mL
    N
    N
    8-OHdG as Biomarker for Breast Cncer
    Figure 1 Serum Levels of 8-OHdG, CA15-3, and CEA Compared Between the Benign and Malignant BC Groups With the Normal Group. ***P < .001
    t
    the medical ethics committee of the Faculty of Medicine at Umm Al-Qura University and the medical ethics committee of King Abdallah Medical City, Makkah, Kingdom of Saudi Arabia. Written informed consent was obtained from every participating patient.
    Determination of Serum Levels of 8-OHdG
    8-OHdG serum levels were determined by a competitive inhi-bition enzyme immunoassay kit, (EU2548, Wuhan Fine Biological Technology Co, Ltd, Wuhan, China) according to the provided assay procedure (http://www.fn-test.com).
    Determination of Serum Levels of CEA
    Serum levels of CEA were determined by an in vitro enzyme-linked immunosorbent assay kit (SEA150Hu, Cloud-Clone Corp, Houston, TX) according to the manufacturer’s instructions and provided assay procedure (http://cloud-clone.com).
    Determination of Serum Levels of CA15-3
    Serum levels of CA15-3 were determined by a solid phase in vitro enzyme-linked immunosorbent assay kit (MBS580044, MyBioSource.Com, San Diego, CA) according to manufacturer’s instructions (http://mybiosource.com).
    Evaluation of Diagnostic Performance of Serum 8-OHdG Using Receiver Operating Characteristic (ROC) Curve Analysis
    n
    o
    C
    B
    C
    e
    control design, so the estimated OR of BC risk was calculated according to quartiles of serum 8-OHdG levels using binary logistic regression analysis.
    Statistical Analysis
    The results were statistically processed by SPSS 24 software using the parametric Student t test and the nonparametric Spearman cor-relation. The differences were considered significant at a P value < .05.
    Relation Between Serum 8-OHdG and the Risk of BC Results (Odds Ratio [OR]) Clinical and Demographic Characteristics of Subjects We assumed symbiosis a high level of the oxidative damage biomarker Blood samples were collected from all patients prior to any treat- 8-OHdG is a risk factor for developing BC. This study was a case fi
    ment. The diagnosis was con rmed by histopathology and clinical
    n